How Chinese Drugs Are Winning Global Approval After 2015

Chinese-developed drugs are no longer rare in global markets. A new study tracks their journey from 1990 to 2025, showing how they gained traction over time. The focus starts in the United States, with Europe and other regions used for comparison.

Researchers looked at official approval records from the MENET database. They also checked public data from regulators. In the U.S., they studied every approval event, including generics, new drugs, and biologics. For Europe, they counted approved products. Other markets were reviewed to see where these drugs spread.

Before 2015, approvals were low. Most were generic drugs. But after 2015, things changed fast. From 2016 to 2020, there were 570 generic approvals. From 2021 to 2025, that number stayed high at 567. New drug approvals jumped too, with 37 approved in just four years. Biologic drugs first showed up in 2022 and grew after 2023.

The types of drugs also shifted. After 2015, most were for cancer, immune issues, heart health, and brain function. Europe approved fewer but focused on similar areas. Many drugs got approved in multiple places at once or one after another. These included cancer and immune treatments across the U.S., Europe, the UK, Japan, Australia, Canada, and beyond.

This trend shows Chinese drugs are becoming more accepted worldwide. It also raises questions about quality, speed, and fairness in global medicine.